Cargando…

The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy

Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiurong, Su, Fangming, Luo, Xin, Ning, Yingxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387205/
https://www.ncbi.nlm.nih.gov/pubmed/34458237
http://dx.doi.org/10.3389/fchem.2021.710250
_version_ 1783742413767966720
author Sun, Xiurong
Su, Fangming
Luo, Xin
Ning, Yingxia
author_facet Sun, Xiurong
Su, Fangming
Luo, Xin
Ning, Yingxia
author_sort Sun, Xiurong
collection PubMed
description Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic side effects, we herein sought to design a novel approach to the low-dose RT treatment of hypoxic tumors using a Tirapazamine (TPZ)-loaded exosome (EXO) nanoplatform (MT). This MT platform was synthesized via loading EXOs with TPZ, which is a prodrug that is activated when exposed to hypoxic conditions. MT application was able to achieve effective tumor inhibition at a relatively low RT dose (2 Gy) that was superior to standard high-dose (6 Gy) RT treatment with specific targeting to the hypoxic region of tumor. RT-mediated oxygen consumption further aggravated hypoxic conditions to improve TPZ activation and treatment efficacy. Together, our findings demonstrate the clinical promise of this MT platform as a novel tool for the efficient radiosensitization and treatment of cancer patients.
format Online
Article
Text
id pubmed-8387205
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83872052021-08-26 The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy Sun, Xiurong Su, Fangming Luo, Xin Ning, Yingxia Front Chem Chemistry Radiotherapy (RT) is a standard treatment strategy for many cancer types, but the need to frequently apply high doses of ionizing radiation in order to achieve therapeutic efficacy can cause severe harm to healthy tissues, leading to adverse patient outcomes. In an effort to minimize these toxic side effects, we herein sought to design a novel approach to the low-dose RT treatment of hypoxic tumors using a Tirapazamine (TPZ)-loaded exosome (EXO) nanoplatform (MT). This MT platform was synthesized via loading EXOs with TPZ, which is a prodrug that is activated when exposed to hypoxic conditions. MT application was able to achieve effective tumor inhibition at a relatively low RT dose (2 Gy) that was superior to standard high-dose (6 Gy) RT treatment with specific targeting to the hypoxic region of tumor. RT-mediated oxygen consumption further aggravated hypoxic conditions to improve TPZ activation and treatment efficacy. Together, our findings demonstrate the clinical promise of this MT platform as a novel tool for the efficient radiosensitization and treatment of cancer patients. Frontiers Media S.A. 2021-08-11 /pmc/articles/PMC8387205/ /pubmed/34458237 http://dx.doi.org/10.3389/fchem.2021.710250 Text en Copyright © 2021 Sun, Su, Luo and Ning. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Sun, Xiurong
Su, Fangming
Luo, Xin
Ning, Yingxia
The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title_full The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title_fullStr The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title_full_unstemmed The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title_short The Use of Bionic Prodrugs for the Enhancement of Low Dose Radiotherapy
title_sort use of bionic prodrugs for the enhancement of low dose radiotherapy
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387205/
https://www.ncbi.nlm.nih.gov/pubmed/34458237
http://dx.doi.org/10.3389/fchem.2021.710250
work_keys_str_mv AT sunxiurong theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT sufangming theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT luoxin theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT ningyingxia theuseofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT sunxiurong useofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT sufangming useofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT luoxin useofbionicprodrugsfortheenhancementoflowdoseradiotherapy
AT ningyingxia useofbionicprodrugsfortheenhancementoflowdoseradiotherapy